|
World Hemophilia Day: Sanofi Genzyme donation impacts patients across the globe
|
17 April 2019 |
|
Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
|
08 April 2019 |
|
Sanofi builds focus on rare blood disorders and cancers
|
29 November 2018 |
|
FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
|
07 November 2018 |
|
FDA approves asthma indication for Dupixent® (dupilumab)
|
22 October 2018 |
|
Sanofi completes divestiture of Zentiva to Advent
|
03 October 2018 |
|
Sanofi and REVOLUTION Medicines launch global partnership to develop potential first-in-class targeted treatments for multiple cancers
|
18 July 2018 |
|
Sanofi and Ablynx announce the successful results of the initial tender offer period
|
14 May 2018 |
|
FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma
|
02 March 2018 |
|
Sanofi to acquire Ablynx for €3.9 Billion
|
29 January 2018 |